Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE
Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias
Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias
View: Text | PDF
Research Article Inflammation

NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE

  • Text
  • PDF
Abstract

IL-33, a nuclear alarmin released during cell death, exerts context-specific effects on adaptive and innate immune cells, eliciting potent inflammatory responses. We screened blood, skin, and kidney tissues from patients with systemic lupus erythematosus (SLE), a systemic autoimmune disease driven by unabated type I IFN production, and found increased amounts of extracellular IL-33 complexed with neutrophil extracellular traps (NETs), correlating with severe, active disease. Using a combination of molecular, imaging, and proteomic approaches, we show that SLE neutrophils, activated by disease immunocomplexes, release IL-33–decorated NETs that stimulate robust IFN-α synthesis by plasmacytoid DCs in a manner dependent on the IL-33 receptor ST2L. IL33-silenced neutrophil-like cells cultured under lupus-inducing conditions generated NETs with diminished interferogenic effect. Importantly, NETs derived from patients with SLE are enriched in mature bioactive isoforms of IL-33 processed by the neutrophil proteases elastase and cathepsin G. Pharmacological inhibition of these proteases neutralized IL-33–dependent IFN-α production elicited by NETs. We believe these data demonstrate a novel role for cleaved IL-33 alarmin decorating NETs in human SLE, linking neutrophil activation, type I IFN production, and end-organ inflammation, with skin pathology mirroring that observed in the kidneys.

Authors

Spiros Georgakis, Katerina Gkirtzimanaki, Garyfalia Papadaki, Hariklia Gakiopoulou, Elias Drakos, Maija-Leena Eloranta, Manousos Makridakis, Georgia Kontostathi, Jerome Zoidakis, Eirini Baira, Lars Rönnblom, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Panayotis Verginis, George Bertsias

×

Figure 7

Neutrophil elastase cleaved NET-bound IL-33 into highly interferogenic bioactive isoforms.

Options: View larger image (or click on image) Download as PowerPoint
Neutrophil elastase cleaved NET-bound IL-33 into highly interferogenic b...
(A) Recombinant (fl)IL-33 was added to cultures of PMA-treated, MSU-treated healthy, unstimulated, or IC-treated SLE neutrophils. After 3 hours, DNase (200 U/mL, 30 minutes, 37°C) was added and NET-proteins were harvested. Immunoblotting revealed band approximately equal to 19 kDa corresponding to protease-generated IL-33 isoform in the supernatants from IC-treated SLE neutrophils. (B) The same assay was repeated using cultures of IC-treated SLE neutrophils pretreated (or not) with sivelestat (2 μΜ). A representative blot of 2 experiments is shown. (C) SLE neutrophils were stimulated with ICs, followed by addition of sivelestat. NETs were collected and administered to pDCs. Supernatants were assayed by ELISA for IFN-α. Each dot represents a different donor (n = 5) and bar plots show the mean ± SEM expression. **P < 0.01 (2-tailed, repeated measures (RM) ANOVA with Holm-Sidak correction). (D) The same experiment as in C was repeated and pDCs were assayed for IRF7 mRNA (n = 9 donors) **P < 0.01 (2-tailed, RM-ANOVA with Holm-Sidak correction). (E) pDCs were cultured with CpG-A (0.1 μΜ) and either (fl)IL-33 (100 nM) or supernatants from the incubation of IC-treated SLE neutrophils with (fl)IL-33 for 4 hours. IL-33 NET-cleaved supernatants were treated with DNAse. pDCs were assayed by flow cytometry for intracellular p-IRF7 mean fluorescence intensity (MFI). Left panel summarizes the results from 5 donors represented by different dots, and right panel illustrates a representative flow cytometry histogram. *P < 0.05 (2-tailed, RM-ANOVA with Holm-Sidak correction). (F) pDCs were cultured with CpG-A and supernatants (2.5% v/v) derived from the in vitro reaction of (fl)IL-33 (1.8 μg/mL) with or without elastase (50 ng/mL). pDCs were assayed for IFNA (left panel) and IRF7 (right panel) mRNA (n = 16 donors). *P < 0.05; **P < 0.01 (2-tailed, RM-ANOVA with Holm-Sidak correction). Spont., spontaneous.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts